Medicine and Health

A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge

Y. Yahalom-ronen, H. Tamir, et al.

This study introduces an innovative VSV-ΔG-spike vaccine to combat SARS-CoV-2, developed by a team from the Israel Institute for Biological Research. The vaccine demonstrated strong safety and efficacy, inducing neutralizing antibodies and providing protection in animal models, showcasing its potential as a robust defense against COVID-19.

00:00

Playback language: English

Index

Abstract

This study presents the development of a replication-competent recombinant VSV-ΔG-spike vaccine, replacing the VSV glycoprotein with the SARS-CoV-2 spike protein. In vitro characterization showed spike protein expression and antigenic similarity to SARS-CoV-2. A single dose in golden Syrian hamsters induced neutralizing antibodies and protected against SARS-CoV-2 challenge, evidenced by reduced weight loss and tissue damage. The vaccine is suggested as a safe and effective option against SARS-CoV-2.

Publisher

Nature Communications

Published On

Dec 16, 2020

Authors

Yfat Yahalom-Ronen, Hadas Tamir, Sharon Melamed, Boaz Politi, Ohad Shifman, Hagit Achdout, Einat B. Vitner, Ofir Israeli, Elad Milrot, Dana Stein, Inbar Cohen-Gihon, Shlomi Lazar, Hila Gutman, Itai Glinert, Lilach Cherry, Yaron Vagima, Shirley Lazar, Shay Weiss, Amir Ben-Shmuel, Roy Avraham, Reut Puni, Edith Lupu, Elad Bar-David, Assa Sittner, Noam Erez, Ran Zichel, Emanuelle Mamroud, Ohad Mazor, Haim Levy, Orly Laskar, Shmuel Yitzhaki, Shmuel C. Shapira, Anat Zvi, Adi Beth-Din, Nir Paran, Tomer Israely

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants

J. Logue, R. M. Johnson, et al.

Medicine and Health

A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration

H. Ma, X. Zhang, et al.

Medicine and Health

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery

X. Zhang, H. Zhang, et al.

Medicine and Health

A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein

W. Pang, Y. Lu, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny